0000000000803373

AUTHOR

Emmanuelle Meugnier

0000-0002-2291-7691

showing 2 related works from this author

Low level activity thresholds for changes in NMR biomarkers and genes in high risk subjects for type 2 diabetes

2017

AbstractOur objectives were to determine if there are quantitative associations between amounts and intensities of physical activities (PA) on NMR biomarkers and changes in skeletal muscle gene expressions in subjects with high risk for type 2 diabetes (T2D) performing a 3-month PA intervention. We found that PA was associated with beneficial biomarker changes in a factor containing several VLDL and HDL subclasses and lipids in principal component analysis (P = <0.01). Division of PA into quartiles demonstrated significant changes in NMR biomarkers in the 2nd - 4th quartiles compared to the 1st quartile representing PA of less than 2850 daily steps (P = 0.0036). Mediation analysis of PA-…

0301 basic medicineBlood GlucoseMaleVery low-density lipoprotein[SDV]Life Sciences [q-bio]prévention des maladieslcsh:MedicineAdipose tissueMuscle ProteinsType 2 diabetes030204 cardiovascular system & hematologyOverweight0302 clinical medicinemaladie cardiovasculairelcsh:ScienceComputingMilieux_MISCELLANEOUSBODY-WEIGHT CHANGEMultidisciplinaryMiddle AgedMagnetic Resonance Imaging[SDV] Life Sciences [q-bio]ADIPOSE-TISSUEBiomarker (medicine)SKELETAL-MUSCLEFemalemedicine.symptombiomarqueurINSULIN-RESISTANCE ATHEROSCLEROSISAutre (Sciences du Vivant)Adultmedicine.medical_specialtydiabète de type 2expression géniqueCarbohydrate metabolismALL-CAUSEArticle03 medical and health sciencesMedical researchLIPID-METABOLISMInternal medicineDiabetes mellitusmedicineAPOLIPOPROTEIN-D POLYMORPHISMHumansObesityNUCLEAR-MAGNETIC-RESONANCEMuscle SkeletalExercisebusiness.industryMORTALITYlcsh:RLipid metabolismsurpoidsLIPOPROTEIN PARTICLE-SIZEmedicine.disease030104 developmental biologyEndocrinologyPHYSICAL-ACTIVITYDiabetes Mellitus Type 2Gene Expression Regulationlcsh:QbusinessBiomarkers
researchProduct

Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat, High-Sucrose Diet Mice Mod…

2015

International audience; Imeglimin is the first in a new class of oral glucose-lowering agents currently in phase 2b development. Although imeglimin improves insulin sensitivity in humans, the molecular mechanisms are unknown. This study used a model of 16-week high-fat, high-sucrose diet (HFHSD) mice to characterize its antidiabetic effects. Six-week imeglimin treatment significantly decreased glycemia, restored normal glucose tolerance, and improved insulin sensitivity without modifying organs, body weights, and food intake. This was associated with an increase in insulin-stimulated protein kinase B phosphorylation in the liver and muscle. In liver mitochondria, imeglimin redirects substra…

Malemedicine.medical_specialtyMale Animals Mice Inbred C57BL Insulin Resistance/*physiology Diet High-Fat/adverse effects Hypoglycemic Agents/*therapeutic use Liver/*drug effects/*metabolism Mitochondria/*drug effects/*metabolism Triazines/*therapeutic useImegliminMitochondria/*drug effects/*metabolismEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]High-Fat/adverse effectsBiologyMitochondrionDiet High-Fatmedicine.disease_causeInbred C57BLchemistry.chemical_compoundMiceLipid oxidationInternal medicineInternal MedicinemedicineHypoglycemic Agents/*therapeutic useHypoglycemic AgentsAnimalsProtein kinase BBeta oxidationComputingMilieux_MISCELLANEOUS2. Zero hungerchemistry.chemical_classificationReactive oxygen speciesTriazines/*therapeutic useTriazinesMitochondria3. Good healthDietMice Inbred C57BL[SDV] Life Sciences [q-bio]EndocrinologyLiver/*drug effects/*metabolismLiverchemistryInsulin Resistance/*physiologyCoenzyme Q – cytochrome c reductaseInsulin ResistanceOxidative stress
researchProduct